businesspress24.com - Inferior Vena Cava Filters (IVCF) Pipeline Analysis with Ongoing Clinical Trials and Recent Developm
 

Inferior Vena Cava Filters (IVCF) Pipeline Analysis with Ongoing Clinical Trials and Recent Developments: 2017 Report

ID: 1499908

Inferior vena cava filters (IVCF) are used in trauma patients to reduce the incidence of pulmonary embolism (PE).

(firmenpresse) - Albany, New York, April 24, 2017: The latest pipeline analysis on the rapidly expanding market of inferior vena cava filters, has been recently broadcasted to the broad portfolio of Market Research Hub (MRH). It is titled as “Inferior Vena Cava Filters (IVCF) - Medical Devices Pipeline Assessment, 2017” and offers a precise overview of these filters, which are currently in the pipeline stage. Additionally, It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and the number of trials for the key Inferior Vena Cava Filters (IVCF) pipeline products.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1054416

In the first section, the readers will get to know about the market overview of Inferior Vena Cava Filter (IVCF). It is a mechanical device used to prevent blood clots from traveling to lungs. IVC filter traps blood clots before it reaches to the lungs. IVC filters are made of non-ferromagnetic materials [Cobalt Chromium Alloy, Stainless Steel, Titanium, Nickel-Titanium (Nitinol)]. The filter is inserted inside a large vein called the inferior vena cava (which carries blood from lower extremities to the heart). Inferior vena cava filters (IVCF) are used in trauma patients to reduce the incidence of pulmonary embolism (PE). It has been analyzed that, the clinically proven and recognized purpose for this product is to prevent blood clots in deep veins, a condition known as Deep Vein Thrombosis (DVT).

There are two versions of IVC filters are available, which includes retrievable and permanent. The majority of these filters used today are permanent. The FDA recommends that implanting physicians and clinicians responsible for the ongoing care of patients with retrievable IVC filters consider eliminating the filter once protection from pulmonary embolism (PE) is no longer required. At present, the market of inferior vena cava filters is majorly driven by rising incidences of cardiovascular diseases globally. This rise in a number of patients diagnosed with cardiovascular diseases across the world will boost the global inferior vena cava filters market.





Moreover, the report extensively covers the details on IVCF under development based on various stages of development ranging from Early Development to Approved / Issued stage. Also, it identifies and understands important and varied types of Inferior Vena Cava Filters (IVCF) which are under development. For the better understanding of the device, this report is prepared using data sourced from in-house databases, secondary and primary research by the team of industry experts.

In the concluding section, the report reviews the major players involved in the development of Inferior Vena Cava Filters (IVCF) and list all their pipeline projects in detail. Here’s a list of major players outlined in this study:

Adient Medical Inc.
Contego Medical, LLC
Interventional & Surgical Innovations, LLC
Veniti Inc
Kaleidoscope
VueKlar Cardiovascular Ltd
Lifetech Scientific (Shenzhen) Co., Ltd.
Volcano Corp

Browse Full Report With TOC: http://www.marketresearchhub.com/report/inferior-vena-cava-filters-ivcf-medical-devices-pipeline-assessment-2017-report.html

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.



Leseranfragen:



PresseKontakt / Agentur:

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press(at)marketresearchhub.com

Follow us on:
Twitter: twitter.com/MktResearchHub
LinkedIn: www.linkedin.com/company/market-research-hub
Facebook: www.facebook.com/MarketResearchHub/



drucken  als PDF  an Freund senden  GrayMeta(TM) Introduces New UI for Platform Solution Ahead of NAB 2017
SpeeDx and Thermo Fisher Scientific Announce Strategic Partnership for FDA Clearance of Molecular Diagnostic
Bereitgestellt von Benutzer: MarketResearchHub
Datum: 24.04.2017 - 03:00 Uhr
Sprache: Deutsch
News-ID 1499908
Anzahl Zeichen: 3529

contact information:
Contact person: Ashwani Kailiya
Town:

Albany


Phone: 5186212074

Kategorie:

Healthcare


Typ of Press Release: Produktinformation
type of sending: Veröffentlichung
Date of sending: 24.04.2017
Anmerkungen:


Diese Pressemitteilung wurde bisher 468 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Inferior Vena Cava Filters (IVCF) Pipeline Analysis with Ongoing Clinical Trials and Recent Developments: 2017 Report
"
steht unter der journalistisch-redaktionellen Verantwortung von

Market Research HUB (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Market Research HUB



 

Who is online

All members: 10 667
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 428


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.